TS Picks: December 30, 2015

Overvaluing startups; undervaluing human research participants; curing aging?

kerry grens
Kerry Grens

Kerry served as The Scientist’s news director until 2021. Before joining The Scientist in 2013, she was a stringer for Reuters Health, the senior health and science reporter at...

View full profile.

Learn about our editorial policies.


Selections from The Scientist’s reading list:

  • This year was marked by investors overshooting the worth of biomed and tech startups, according to The Verge. Theranos, a blood diagnostics company whose underlying science has been met with considerable skepticism, was the prime example of “startups whose valuation was way out of whack,” The Verge reported. “Right now, there’s a lot of cheerleading for ‘disruptive’ opportunities among VCs [venture capitalists]. What many firms seem not to understand is that though there are massive revenue opportunities in health care, ‘disrupting’ patients’ lives can lead to death.”
  • In advance of the 50th anniversary of a seminal paper on human research ethics, medical historian Susan Lederer of the University of Wisconsin School of Medicine and Public Health discussed in this month’s issue of AMA Journal of Ethics how the media, public, and medical community have valued the...

Interested in reading more?

The Scientist ARCHIVES

Become a Member of

Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member?